相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Feasibility of reconstructed ancestral H5N1 influenza viruses for cross-clade protective vaccine development
Mariette F. Ducatez et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Vaccine adjuvants alum and MF59 induce rapid recruitment of neutrophils and monocytes that participate in antigen transport to draining lymph nodes
Samuele Calabro et al.
VACCINE (2011)
Comparison of Half and Full Doses of an MF59-Adjuvanted Cell Culture-Derived A/H1N1v Vaccine in Japanese Children
Yuji Yasuda et al.
ADVANCES IN THERAPY (2010)
A Heterologous MF59-Adjuvanted H5N1 Prepandemic Influenza Booster Vaccine Induces a Robust, Cross-Reactive Immune Response in Adults and the Elderly
Elena Fragapane et al.
CLINICAL AND VACCINE IMMUNOLOGY (2010)
Recipients of Vaccine against the 1976 Swine Flu Have Enhanced Neutralization Responses to the 2009 Novel H1N1 Influenza Virus
Jonathan A. McCullers et al.
CLINICAL INFECTIOUS DISEASES (2010)
Monitoring Adverse Events of the Vaccination Campaign Against Influenza A (H1N1) in the Netherlands
Eugene P. van Puijenbroek et al.
DRUG SAFETY (2010)
Prior infection with classical swine H1N1 influenza viruses is associated with protective immunity to the 2009 pandemic H1N1 virus
John C. Kash et al.
INFLUENZA AND OTHER RESPIRATORY VIRUSES (2010)
Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine
Davide Corti et al.
JOURNAL OF CLINICAL INVESTIGATION (2010)
Immunity to Pre-1950 H1N1 Influenza Viruses Confers Cross-Protection against the Pandemic Swine-Origin 2009 A (H1N1) Influenza Virus
Ioanna Skountzou et al.
JOURNAL OF IMMUNOLOGY (2010)
Multiple Infections with Seasonal Influenza A Virus Induce Cross-Protective Immunity against A(H1N1) Pandemic Influenza Virus in a Ferret Model
Karen L. Laurie et al.
JOURNAL OF INFECTIOUS DISEASES (2010)
Vaccinate before the next pandemic?
Klaus Stoehr
NATURE (2010)
Research and development of universal influenza vaccines
Lanying Du et al.
MICROBES AND INFECTION (2010)
Responses to 2009 H1N1 Vaccine in Children 3 to 17 Years of Age
Adriano Arguedas et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Immunogenicity and Safety of MF59-Adjuvanted H5N1 Influenza Vaccine From Infancy to Adolescence
Timo Vesikari et al.
PEDIATRICS (2010)
Vaccines with MF59 Adjuvant Expand the Antibody Repertoire to Target Protective Sites of Pandemic Avian H5N1 Influenza Virus
Surender Khurana et al.
SCIENCE TRANSLATIONAL MEDICINE (2010)
Global production of seasonal and pandemic (H1N1) influenza vaccines in 2009-2010 and comparison with previous estimates and global action plan targets
Jeffrey Partridge et al.
VACCINE (2010)
Antibody response against heterogeneous circulating influenza virus strains elicited by MF59-and non-adjuvanted vaccines during seasons with good or partial matching between vaccine strain and clinical isolates
Filippo Ansaldi et al.
VACCINE (2010)
Safety of MF59-adjuvanted versus non-adjuvanted influenza vaccines in children and adolescents: An integrated analysis
Steven Black et al.
VACCINE (2010)
Dose ranging of adjuvant and antigen in a cell culture H5N1 influenza vaccine: Safety and immunogenicity of a phase 1/2 clinical trial
Wendy Keitel et al.
VACCINE (2010)
Priming with AS03A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: An open non-randomised extension of a double-blind randomised primary study
Isabel Leroux-Roels et al.
VACCINE (2010)
Exposure to MF59-adjuvanted influenza vaccines during pregnancy-A retrospective analysis
Theodore Tsai et al.
VACCINE (2010)
Immunogenicity, Safety, and Cross-Reactivity of an Inactivated, Adjuvanted, Prototype Pandemic Influenza (H5N1) Vaccine: A Phase II, Double-Blind, Randomized Trial
Jiang Wu et al.
CLINICAL INFECTIOUS DISEASES (2009)
Prepandemic H5N1 influenza vaccine adjuvanted with AS03: a review of the pre-clinical and clinical data
Geert Leroux-Roels
EXPERT OPINION ON BIOLOGICAL THERAPY (2009)
A Cell Culture (Vero)-Derived H5N1 Whole-Virus Vaccine Induces Cross-Reactive Memory Responses
Hartmut J. Ehrlich et al.
JOURNAL OF INFECTIOUS DISEASES (2009)
Universal epitopes of influenza virus hemagglutinins?
Taia T. Wang et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2009)
Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses
Jianhua Sui et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2009)
Response to a Monovalent 2009 Influenza A (H1N1) Vaccine.
Michael E. Greenberg et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Trial of 2009 Influenza A (H1N1) Monovalent MF59-Adjuvanted Vaccine.
Tristan W. Clark et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
MF59®-Adjuvanted H5N1 Vaccine Induces Immunologic Memory and Heterotypic Antibody Responses in Non-Elderly and Elderly Adults
Angelika Banzhoff et al.
PLOS ONE (2009)
Enhanced Immunogenicity of Seasonal Influenza Vaccines in Young Children Using MF59 Adjuvant
Timo Vesikari et al.
PEDIATRIC INFECTIOUS DISEASE JOURNAL (2009)
Fast rise of broadly cross-reactive antibodies after boosting long-lived human memory B cells primed by an MF59 adjuvanted prepandemic vaccine
Grazia Galli et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Adjuvanted H5N1 vaccine induces early CD4+ T cell response that predicts long-term persistence of protective antibody levels
Grazia Galli et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Antibody Recognition of a Highly Conserved Influenza Virus Epitope
Damian C. Ekiert et al.
SCIENCE (2009)
Seasonal Influenza Vaccine Provides Priming For A/H1N1 Immunization
Giuseppe Del Giudice et al.
SCIENCE TRANSLATIONAL MEDICINE (2009)
Pseudoparticle neutralization is a reliable assay to measure immunity and cross-reactivity to H5N1 influenza viruses
Isabella Alberini et al.
VACCINE (2009)
Antibodies to squalene in US Navy Persian Gulf War veterans with chronic multisymptom illness
Christopher J. Phillips et al.
VACCINE (2009)
Single- and multiple-clade influenza A H5N1 vaccines induce cross protection in ferrets
Heather L. Forrest et al.
VACCINE (2009)
Immunogenicity and tolerability of an AS03A-adjuvanted prepandemic influenza vaccine: A phase III study in a large population of Asian adults
Daniel Wai-Sing Chu et al.
VACCINE (2009)
Adjuvanted seasonal influenza vaccines and perpetual viral metamorphosis: The importance of cross-protection
Filippo Ansaldi et al.
VACCINE (2009)
MF59®-adjuvanted influenza vaccine (FLUAD®) in children: Safety and immunogenicity following a second year seasonal vaccination
T. Vesikari et al.
VACCINE (2009)
Cross-reactive antibodies in middle-aged and elderly volunteers after MF59-adjuvanted subunit trivalent influenza vaccine against B viruses of the B/Victoria or B/Yamagata lineages
B. Camilloni et al.
VACCINE (2009)
MF59-adjuvanted versus non-adjuvanted influenza vaccines: Integrated analysis from a large safety database
Michele Pellegrini et al.
VACCINE (2009)
Antigenic Fingerprinting of H5N1 Avian Influenza Using Convalescent Sera and Monoclonal Antibodies Reveals Potential Vaccine and Diagnostic Targets
Surender Khurana et al.
PLOS MEDICINE (2009)
Seasonal and pandemic influenza: A 2007 update on challenges and solutions
Arnold S. Monto et al.
CLINICAL INFECTIOUS DISEASES (2008)
The adjuvants aluminum hydroxide and MF59 induce monocyte and granulocyte chemoattractants and enhance monocyte differentiation toward dendritic cells
Anja Seubert et al.
JOURNAL OF IMMUNOLOGY (2008)
An adjuvanted, low-dose, pandemic influenza a (H5N1) vaccine candidate is safe, immunogenic, and induces cross-reactive immune responses in healthy adults
Karin Levie et al.
JOURNAL OF INFECTIOUS DISEASES (2008)
Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults
David I. Bernstein et al.
JOURNAL OF INFECTIOUS DISEASES (2008)
Evaluation of the safety and immunogenicity of a booster (third) dose of inactivated subvirion H5N1 influenza vaccine in humans
Kenneth M. Zangwill et al.
JOURNAL OF INFECTIOUS DISEASES (2008)
Stockpiling prepandemic influenza vaccines: a new cornerstone of pandemic preparedness plans
Lance C. Jennings et al.
LANCET INFECTIOUS DISEASES (2008)
Antigenically distinct MF59-adjuvanted vaccine to boost immunity to H5N1
Iain Stephenson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
A clinical trial of a whole-virus H5N1 vaccine derived from cell culture
Hartmut J. Ehrlich et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Broad Clade 2 Cross-Reactive Immunity Induced by an Adjuvanted Clade 1 rH5N1 Pandemic Influenza Vaccine
Isabel Leroux-Roels et al.
PLOS ONE (2008)
Cross-Protection against Lethal H5N1 Challenge in Ferrets with an Adjuvanted Pandemic Influenza Vaccine
Benoit Baras et al.
PLOS ONE (2008)
Heterosubtypic Neutralizing Monoclonal Antibodies Cross-Protective against H5N1 and H1N1 Recovered from Human IgM+ Memory B Cells
Mark Throsby et al.
PLOS ONE (2008)
Molecular and cellular signatures of human vaccine adjuvants
F. Mosca et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Combination adjuvants for the induction of potent, long-lasting antibody and T-cell responses to influenza vaccine in mice
Andreas Wack et al.
VACCINE (2008)
Cross-protection by MF59™-adjuvanted influenza vaccine:: Neutralizing and haemagglutination-inhibiting antibody activity against A(H3N2) drifted influenza viruses
Filippo Ansaldi et al.
VACCINE (2008)
The requirement of CD80, CD86, and ICAM-1 on the ability of adjuvant formulations to potentiate antibody responses to a Plasmodium falciparum blood-stage vaccine
George Hui et al.
VACCINE (2007)
Effectiveness of MF59™-adjuvanted subunit influenza vaccine in preventing hospitalisations for cardiovascular disease, cerebrovascular disease and pneumonia in the elderly
Joan Puig-Barbera et al.
VACCINE (2007)
MF59 is a safe and potent vaccine adjuvant that enhances protection against influenza virus infection
Derek T. O'Hagan
EXPERT REVIEW OF VACCINES (2007)
Influenza vaccine: The challenge of antigenic drift
F. Carrat et al.
VACCINE (2007)
Response of influenza vaccines against heterovariant influenza virus strains in adults with chronic diseases
V. Baldo et al.
JOURNAL OF CLINICAL IMMUNOLOGY (2007)
MF59-adjuvanted influenza vaccine confers superior immunogenicity in adult subjects (18-60 years of age) with chronic diseases who are at risk of post-influenza complications
V. Baldo et al.
VACCINE (2007)
Real-time monitoring of the influenza vaccine field effectiveness
Judith Legrand et al.
VACCINE (2006)
Vaccines with the MF59 adjuvant do not stimulate antibody responses against squalene
Giuseppe Del Giudice et al.
CLINICAL AND VACCINE IMMUNOLOGY (2006)
An MF59-adjuvanted inactivated influenza vaccine containing A/Panama/1999 (H3N2) induced broader serological protection against heterovariant influenza virus strain A/Fujian/2002 than a subunit and a split influenza vaccine
G Del Giudice et al.
VACCINE (2006)
A preliminary evaluation of alternative adjuvants to alum using a range of established and new generation vaccine antigens
M Singh et al.
VACCINE (2006)
Antibody response to influenza vaccination in the elderly: A quantitative review
K Goodwin et al.
VACCINE (2006)
Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza A/duck/Singapore/97 (H5N3) vaccine: A potential priming strategy
I Stephenson et al.
JOURNAL OF INFECTIOUS DISEASES (2005)
Effectiveness of the MF59-adjuvanted influenza vaccine in preventing emergency admissions for pneumonia in the elderly over 64 years of age
J Puig-Barberà et al.
VACCINE (2004)
Antibody responses and HIV-1 viral load in HIV-1-seropositive subjects immunised with either the MF59-adjuvanted influenza vaccine or a conventional non-adjuvanted subunit vaccine during highly active antiretroviral therapy
AM Iorio et al.
VACCINE (2003)
A new MF59-adjuvanted influenza vaccine enhances the immune response in the elderly with chronic diseases: Results from an immunogenicity meta-analysis
A Banzhoff et al.
GERONTOLOGY (2003)
Boosting immunity to influenza H5N1 with MF59-adjuvanted H5N3 A/Duck/Singapore/97 vaccine in a primed human population
I Stephenson et al.
VACCINE (2003)
Comparison of the reactogenicity and immunogenicity of a split and a subunit-adjuvanted influenza vaccine in elderly subjects
S Squarcione et al.
VACCINE (2003)
Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza
KG Nicholson et al.
LANCET (2001)
The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine
A Podda
VACCINE (2001)
分享论文
